1 reports of this reaction
1.4% of all PELARGONIUM SIDOIDES reports
#10 most reported adverse reaction
ACUTE HEPATIC FAILURE is the #10 most commonly reported adverse reaction for PELARGONIUM SIDOIDES, manufactured by Schwabe North America. There are 1 FDA adverse event reports linking PELARGONIUM SIDOIDES to ACUTE HEPATIC FAILURE. This represents approximately 1.4% of all 71 adverse event reports for this drug.
Patients taking PELARGONIUM SIDOIDES who experience acute hepatic failure should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE HEPATIC FAILURE is a less commonly reported adverse event for PELARGONIUM SIDOIDES, but still significant enough to appear in the safety profile.
In addition to acute hepatic failure, the following adverse reactions have been reported for PELARGONIUM SIDOIDES:
The following drugs have also been linked to acute hepatic failure in FDA adverse event reports:
ACUTE HEPATIC FAILURE has been reported as an adverse event in 1 FDA reports for PELARGONIUM SIDOIDES. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE HEPATIC FAILURE accounts for approximately 1.4% of all adverse event reports for PELARGONIUM SIDOIDES, making it a notable side effect.
If you experience acute hepatic failure while taking PELARGONIUM SIDOIDES, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.